Literature DB >> 3082764

Alteration of hemostasis associated with cefoperazone treatment.

K Andrassy, J Koderisch, S Fritz, H Bechtold, H Sonntag.   

Abstract

21 Patients with normal and impaired renal function were given cefoperazone in a recommended dose of 4 g/day, irrespective of renal function. Platelet function and plasmatic coagulation were analyzed before and on day 7 of therapy. In patients with normal renal function on their usual diets, there was neither impairment of platelet function nor plasmatic coagulation. High serum antibiotic trough levels, prolongation of bleeding time and decreased vitamin K-dependent coagulation factors, as verified by the prolongation of prothrombin time and the appearance of descarboxyprothrombin, could be observed in those patients with impaired renal function whose insufficiency was far advanced and accompanied by a complex clinical picture. In this situation vitamin K deficiency may be due to poor oral intake, along with interference of hepatic vitamin K metabolism, showing an effect similar to that seen after coumarin therapy. Dosage reduction of the antibiotic in advanced renal failure and repeated control of prothrombin time is advised.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082764     DOI: 10.1007/bf01644806

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

1.  Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man.

Authors:  M J Shearer; A McBurney; A M Breckenridge; P Barkhan
Journal:  Clin Sci Mol Med       Date:  1977-06

2.  Cefoperazone-induced coagulopathy.

Authors:  S W Parker; J Baxter; T R Beam
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

Review 3.  [Hepatic clearance of drugs in kidney failure].

Authors:  L Balant
Journal:  Nephrologie       Date:  1983

4.  On the mechanism of salicylate-induced hypothrombinaemia.

Authors:  B K Park; J B Leck
Journal:  J Pharm Pharmacol       Date:  1981-01       Impact factor: 3.765

5.  Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole.

Authors:  C A Hooper; B B Haney; H H Stone
Journal:  Lancet       Date:  1980-01-05       Impact factor: 79.321

6.  Hemorrhage, diarrhea, and superinfection associated with the use of moxalactam.

Authors:  A P Panwalker; J Rosenfeld
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

7.  Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins.

Authors:  H Bechtold; K Andrassy; E Jähnchen; J Koderisch; H Koderisch; L S Weilemann; H G Sonntag; E Ritz
Journal:  Thromb Haemost       Date:  1984-07-29       Impact factor: 5.249

Review 8.  Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function.

Authors:  R A Greenfield; A U Gerber; W A Craig
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

9.  Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.

Authors:  J Reddy; R R Bailey
Journal:  N Z Med J       Date:  1980-11-26

10.  Effects of moxalactam on blood coagulation and platelet function.

Authors:  N U Bang; S S Tessler; R O Heidenreich; C A Marks; L E Mattler
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec
View more
  3 in total

1.  Pharmacokinetics and hemostasis following administration of a new, injectable oxacephem (6315-S, flomoxef) in volunteers and in patients with renal insufficiency.

Authors:  K Andrassy; J Koderisch; K Gorges; H Sonntag; K Hirauchi
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Hemostasis in patients with normal and impaired renal function under treatment with cefodizime.

Authors:  K Andrassy; J Koderisch; D Trenk; E Jähnchen; A Iwand
Journal:  Infection       Date:  1987       Impact factor: 3.553

3.  Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature.

Authors:  ZhuYing Cai; Wei Yang; YingYing He; Qingge Chen; ShiQiang Wang; Xuming Luo; Xiongbiao Wang
Journal:  Drug Saf Case Rep       Date:  2016-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.